Can I take colchicine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

You should not take colchicine without consulting a healthcare provider, as it is a prescription medication that requires careful evaluation of your medical history, current conditions, and other medications. Colchicine is primarily used to treat gout attacks and prevent gout flares, and is also used for conditions like familial Mediterranean fever and pericarditis. The typical dose for acute gout is 1.2 mg followed by 0.6 mg one hour later, with a maximum of 1.8 mg in the first 24 hours, as recommended by the 2016 updated EULAR evidence-based recommendations for the management of gout 1. For prevention, doses usually range from 0.5-0.6 mg once or twice daily. Colchicine can cause serious side effects including gastrointestinal issues (nausea, vomiting, diarrhea), muscle weakness, and blood disorders, as reported in a systematic review in support of an American College of Physicians clinical practice guideline 1. It interacts with many medications, particularly certain antibiotics and statins, which can increase toxicity risk, as noted in the 2012 American College of Rheumatology guidelines for management of gout 1. People with kidney or liver disease may need dose adjustments, and colchicine should be avoided in patients with severe renal impairment or those receiving strong P-glycoprotein and/or CYP3A4 inhibitors, as recommended by the 2016 updated EULAR evidence-based recommendations for the management of gout 1. Due to these considerations, colchicine should only be taken under medical supervision with proper evaluation of your specific situation by a healthcare provider, as emphasized in the management of gout guidelines 1.

From the FDA Drug Label

Do not take Colchicine Tablets, USP if you have liver or kidney problems and you take certain other medicines. Before you take Colchicine Tablets, USP tell your healthcare provider about all your medical conditions, including if you: have liver or kidney problems.

You should not take colchicine without first consulting your healthcare provider, especially if you have certain medical conditions such as liver or kidney problems, or if you are taking other medications that may interact with colchicine 2.

From the Research

Considerations for Taking Colchicine

  • Colchicine is a standard treatment for acute gout flare-ups, but its use should be carefully considered due to its narrow therapeutic index and potential for overdose 3.
  • The dosage of colchicine should be adapted to renal function and age, and possible drug interactions should be taken into account 4.
  • Colchicine can be used to manage various conditions, including gout, familial Mediterranean fever, amyloidosis, Behçet's syndrome, recurrent pericarditis, and calcium pyrophosphate deposition disease 3.

Alternatives and Contraindications

  • Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are alternative treatment options for acute gout, but their use may be limited by comorbidities 4, 5.
  • Colchicine may not be suitable for patients with severe renal or hepatic dysfunction, gastrointestinal intolerance, or potential drug interactions 6.
  • NSAID therapy is not recommended in older patients with congestive heart failure, renal failure, or gastrointestinal problems 6.

Patient Characteristics and Treatment Outcomes

  • Patients with gout often have significant comorbidities, such as hypertension, hyperlipidemia, diabetes mellitus, and cardiovascular disease 7.
  • The management of gout in older adults requires careful selection of treatment based on potential benefits and consequences of therapy, considered in tandem with individual patient-specific characteristics 6.
  • Febuxostat may be preferred in older patients with mild to moderate renal disease, as it does not require dose adjustment in these cases 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Treatment of gout].

La Revue de medecine interne, 2011

Research

The management of gout.

Australian prescriber, 2016

Research

Management of gout in the older adult.

The American journal of geriatric pharmacotherapy, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.